About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.